



# Salbutamol ameliorates skeletal muscle wasting and inflammatory markers in streptozotocin (STZ)-induced diabetic rats

Anand Kumar<sup>a</sup>, Priyanka Prajapati<sup>a</sup>, Vinit Raj<sup>b</sup>, Seong-Cheol Kim<sup>b</sup>, Vikas Mishra<sup>a,\*</sup>, Chaitany Jayprakash Raorane<sup>b,\*</sup>, Ritu Raj<sup>c</sup>, Dinesh Kumar<sup>c</sup>, Sapana Kushwaha<sup>d,\*</sup>

<sup>a</sup> Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareilly Road, Lucknow 226025, India

<sup>b</sup> School of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea

<sup>c</sup> Centre of Biomedical Research, SGPGIMS Campus, Lucknow 226014, India

<sup>d</sup> National Institutes of Pharmaceutical Education and Research (NIPER), Raebareilly, Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Lucknow 226002, India

## ARTICLE INFO

### Keywords:

Diabetes  
Streptozotocin  
Salbutamol  
Skeletal muscle atrophy  
Metabolomics

## ABSTRACT

Diabetes accelerates muscle atrophy, leading to the deterioration of skeletal muscles. This study aimed to assess the potential of the  $\beta_2$ -adrenoceptor agonist, salbutamol (SLB), to alleviate muscle atrophy in streptozotocin (STZ)-induced diabetic rats. Male Sprague Dawley rats were randomized into four groups (n=6): control, SLB, STZ (55 mg/kg, single *i.p.*), and STZ + SLB (6 mg/kg, orally for 4 weeks). After the final SLB dose, animals underwent tests to evaluate muscle strength and coordination, including forelimb grip strength, wire-hanging, actophotometer, rotarod, and footprint assessments. Rats were then sacrificed, and serum and gastrocnemius (GN) muscles were collected for further analysis. Serum evaluations included proinflammatory markers (tumor necrosis factor  $\alpha$ , interleukin-1 $\beta$ , interleukin-6), muscle markers (creatinine kinase, myostatin), testosterone, and lipidemic markers. Muscle oxidative stress (malonaldehyde, protein carbonyl), antioxidants (glutathione, catalase, superoxide dismutase), and histology were also performed. Additionally, <sup>1</sup>H nuclear magnetic resonance serum profiling was conducted. SLB notably enhanced muscle grip strength, coordination, and antioxidant levels, while reduced proinflammatory markers and oxidative stress in STZ-induced diabetic rats. Reduced serum muscle biomarkers, increased testosterone, restored lipidemic levels, and improved muscle cellular architecture indicated SLB's positive effect on muscle condition in diabetic rats. Metabolomics profiling revealed that the STZ group significantly increased the phenylalanine-to-tyrosine ratio (PTR), lactate-to-pyruvate ratio (LPR), acetate, succinate, isobutyrate, and histidine. SLB administration restored these perturbed serum metabolites in the STZ-induced diabetic group. In conclusion, salbutamol significantly protected against skeletal muscle wasting in STZ-induced diabetic rats.

## 1. Introduction

Type 1 diabetes mellitus (T1DM) is linked to subsequent complications, encompassing retinopathy, nephropathy, cardiomyopathy, neuropathy, and myopathy [1,2]. Myopathy associated with diabetes is distinguished by the degradation of the structural arrangement of skeletal muscles, along with diminishing functional and metabolic capacities [3]. This progression ultimately leads to symptoms such as muscle

pain, weakness, and muscle atrophy. Both experimental and clinical evidence have demonstrated that elevated blood glucose levels in both type 1 and type 2 diabetes contribute to a decline in muscle strength and muscle loss [4–6]. Nonetheless, this phenomenon can also arise due to a variety of other conditions, including cancer, AIDS, sepsis, burn injuries, organ malfunction, or respiratory and metabolic disorders [7]. Hyperglycemia undeniably plays a significant role in exacerbating muscle deterioration in diabetes. However, it's crucial to acknowledge the

**Abbreviations:** CK, creatine kinase; GDF-8, growth differentiation factor-8; LDL, low-density lipoprotein; MDA, malondialdehyde; SLB, salbutamol; SD, Sprague-Dawley rat; SOD, superoxide dismutase; STZ, streptozotocin; UPS, ubiquitin–proteasome system; TC, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; and T1DM, type 1 diabetes mellitus.

\* Corresponding authors.

E-mail addresses: [dr.vikasmishra@bbau.ac.in](mailto:dr.vikasmishra@bbau.ac.in) (V. Mishra), [chaitanyaraorane22@ynu.ac.kr](mailto:chaitanyaraorane22@ynu.ac.kr) (C.J. Raorane), [sapana.k@niperraebareilly.edu.in](mailto:sapana.k@niperraebareilly.edu.in), [sapana.kushwaha@niperrbl.ac.in](mailto:sapana.kushwaha@niperrbl.ac.in) (S. Kushwaha).

<https://doi.org/10.1016/j.intimp.2023.110883>

Received 18 May 2023; Received in revised form 13 August 2023; Accepted 29 August 2023

Available online 2 September 2023

1567-5769/© 2023 Elsevier B.V. All rights reserved.